Fig. 1From: Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world settingProgression-free survival (a) and overall survival (a) in two groups. T + C, EGFR-TKI combined with chemotherapy; T, EGFR-TKI monotherapy; PFS, progression-free survival; OS, overall survivalBack to article page